% | $
Quotes you view appear here for quick access.

Repros Therapeutics Inc. Message Board

  • dmp2122003 dmp2122003 Jan 30, 2013 9:43 AM Flag

    Repros Therapeutics weakness creates buying opportunity, says Roth Capital

    After Repros' stock sold off yesterday, Roth Capital spoke with the company's management and is more confident that the outlook for the company's Androxal drug remains positive. The firm maintains a $19 price target and Buy rating on the stock.

    Sentiment: Strong Buy

2.42+0.02(+0.83%)Apr 28 4:00 PMEDT